Pernix Therapeutics Holdings Inc. (NYSE: PTX) will purchase Cypress Pharmaceutical Inc., a privately-held company that makes generic pharmaceuticals, and Hawthorn Pharmaceuticals Inc., a company that makes branded pharmaceuticals for up to $101 million.

The buyer, a specialty pharmaceutical company based in the Woodlands, Texas, will make an upfront payment of $68.5 million in cash and $12.5 million in equity. The company has a $60 million credit facility arranged by MidCap Financial.

Both targets are headquartered in Madison, Miss., and combined have about $50 million in revenue.

Pernix expects the deal to increase its branded and generic portfolio. The deal is subject to regulatory approval.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.